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Resumo 
O carcinoma urotelial da bexiga (CUB) é um grave problema de saúde, com elevada taxa de 
morbilidade e mortalidade devido à sua elevada heterogeneidade tanto no comportamento 
clinico como na histogénese. Os protocolos terapêuticos de rotina não são eficazes para todos 
os doentes com CUB tanto superficial como invasor. Neste momento novos fármacos estão em 
desenvolvimento, nomeadamente inibidores do mTOR, com novos alvos terapêuticos. 
O alvo da rapamicina nos mamíferos mTOR (mTOR), a jusante da via de sinalização 
fosfatidilinositol 3-cinase (PI3K)/Akt, possui um papel chave na regulação do metabolismo 
celular, crescimento, proliferação e sobrevivência; alterações nesta via são comuns em variadas 
patologias oncológicas, nomeadamente no carcinoma da bexiga. 
 A glicosilação alterada ou aberrante é comum a vários tipos de carcinomas, nomeadamente 
durante a progressão tumoral alterando a adesão e mobilidade celular, promovendo a invasão 
e metastização. A glicosilação aberrante é responsável pela expressão de carbohidratos 
associados à malignidade e é catalisada por glicosiltransferases e glicosidases específicas. O 
antigénio sialino – STn, associado ao cancro é um produto aberrante da glicosilisação, expresso 
em variados tipos de carcinomas, como ovárico, gástrico, colon e carcinoma da bexiga. A 
existência de uma possível correlação entre a expressão do STn e a via de sinalização mTOR em 
tumores avançados poderá ajudar na estratificação de doentes bem como no desenvolvimento 
de novas estratégias terapêuticas.  
O objetivo principal deste conjunto de estudos foi avaliar a expressão de moléculas da via de 
sinalização PI3K/AKT/mTOR e do STn nos tumores humanos e correlacionar a sua expressão 
com o prognóstico dos doentes.  
Observámos que moléculas a montante e a jusante da via PI3K/AKT/mTOR demonstravam igual 
expressão comparando carcinomas da bexiga não musculo-invasores e musculo-invasores e não 
se relacionavam com o estado da doença; a expressão de PTEN estava diminuída em tumores 
avançados relacionando-se com uma baixa sobrevida. Também, encontramos uma associação 
entre a expressão de STn e a invasão muscular, correlacionada com a sobrevida. Esta tendência 
também foi observada em tumores com expressão de pAkt, pmTOR e/ou pS6 nos grupos STn 
positivos nos tumores musculo-invasores.  
Posteriormente foi avaliada a expressão de moléculas da via de sinalização PI3K/AKT/mTOR e 
do STn em linhas celulares e modelos animais para perceber o efeito dos inibidores mTOR na 
proliferação e sobrevivência das células tumorais.  
Nos carcinomas uroteliais da bexiga induzidos quimicamente em roedores fomos analisar o 
impacto do sirolimus - um inibidor do mTOR na progressão tumoral. Verificámos que os 
roedores tratados apresentavam um menor número de lesões invasivas em paralelo com a 
expressão diminuída de pS6 e STn. Pela primeira vez descrevemos que a administração de 
sirolimus é eficaz em células STn positivas, o que mostra uma possível ligação entre a via de 
sinalização PI3K/AKT/mTOR e o STn em tumores invasivos. 
Relativamente aos inibidores do mTOR avaliámos a eficácia da combinação everolimus 
(RAD001) com cisplatina em linhas celulares de carcinoma urotelial da bexiga. Observámos que 
esta combinação levava à diminuição da proliferação celular num racio dependente da dose, 
em comparação com o fármaco sozinho, nomeadamente nos tumores não invasores da camada 
muscular. 
Fomos também avaliar de que forma a expressão de moléculas da via de sinalização 
PI3K/AKT/mTOR e do STn se correlacionam com o crescimento tumoral e caquexia. 
Em relação à via de sinalização PI3K/AKT/mTOR e a perda de peso muscular nos CUB, 
verificámos, em roedores, que havia uma perda de 17% no peso-caquexia; os níveis diminuídos 
de pAKT, mTOR e p70S6K sugerem uma supressão da via PI3K/AKT/mTOR. 
Observando a correlação da expressão de STn nos CUB com proliferação tumoral e a sua 
relevância clinica, vimos que 75% dos tumores de alto grau que expressavam STn apresentavam 
elevados níveis de proliferação celular e alto risco de recorrência/progressão. A expressão de 
STn correlacionou-se com a capacidade invasiva e esta não era detetada no urotélio normal. 
Relativamente aos estudos usando ratinhos xenógrafos fomos estudar o modelo tumoral de 
CUB. Olhando para a expressão dos marcadores tumorais p53, p63, KI-67, CK20 e STn 
 
 
encontramos similaridades entre os tumores primários e os xenógrafos embora a expressão de 
p53 e KI-67 se encontrasse aumentada; nos xenógrafos a expressão de STn mantinha-se apesar 
de diminuída fazendo deste um bom modelo a usar para estudos de CUB. 
Em suma, os nossos resultados demonstram a ativação da via PI3K/AKT/mTOR em carcinomas 
não-invasores e invasores da camada muscular; esta é um fator chave na carcinogénese 
urotelial da bexiga e como tal, os inibidores do mTOR apresentam um grande potencial como 
novas drogas neste tipo de carcinoma, apresentando elevada eficácia e baixa citotoxicidade. 
 
  
Abstract 
Urothelial carcinoma of the bladder (UCB) is a serious health problem with high mortality and 
morbidity rate due to its heterogeneity associated with clinical behaviour and histogenesis. 
Current therapeutical protocols are not effective for every group of patients with UCB, either 
superficial or invasive. Several compounds are in clinical development with new therapeutic 
targets in bladder cancer namely mTOR inhibitors. 
The Mammalian target of rapamycin (mTOR), a downstream mediator in the phosphoinositide 
3-kinase (PI3K)/Akt signaling pathway, plays an important role in the regulation of cell 
metabolism, growth, proliferation and survival and alterations in this pathway are common of 
several malignant diseases including bladder cancer. 
 Altered or aberrant glycosylation is common in several human carcinomas, especially during 
tumour progression, modifying cellular adhesion and motility, affecting their invasive and 
metastatic potential. Aberrant glycosylation is responsible for the characteristic carbohydrate 
expression associated with malignant transformation, being catalyzed by specific 
glycosyltransferases and glycosidases. STn-cancer-associated sialyl-Tn antigen the product of an 
abnormal glycosylation. STn is expressed in many human carcinomas like ovarian, gastric, colon 
and also bladder cancer. The possible existence of expression of STn and mTOR pathway 
activation in more advanced tumours of the bladder could help in patients stratification as well 
as to design new strategy therapeutics.  
The main goal of the present set of studies was to evaluate the expression of PI3K/AKT/mTOR 
pathway activation and STn in UBC both in human tumours correlating its expression with 
patients prognosis.  
We found that PI3K/AKT/mTOR upstream and downstream related molecules showed an equal 
distribution between non-muscle invasive bladder cancer and muscle-invasive bladder cancer 
(NMIBC and MIBC), not associating with the stage of the disease. PTEN expression was 
decreased in advanced stage tumours and correlated with worse overall survival.  We also 
found an association with STn expression and muscle
 
 
survival. This trend was also found in tumours presenting pAkt, pmTOR and/or pS6 in MIBC STn 
positive groups. 
After we evaluated the expression of PI3K/AKT/mTOR pathway activation and STn in cell lines 
and animal models to understand the effect of the mTOR inhibitors on survival and 
proliferation of tumoral cells. 
In murine chemically induced urothelial tumours we analyzed the impact of sirolimus – an 
mTOR inhibitor on tumoral progression. We found that the treated mice presented a decreased 
number of invasive tumours in parallel with decreased expression of pS6 and STn; we describe 
for the first time that the administration of sirolimus was effective against STn positive cells 
providing an apparently link between PI3K/AKT/mTOR activation and STn in invasive tumours. 
Regarding the mTOR inhibitors we also evaluated the effectiveness of the combination of 
everolimus (RAD001) with cisplatin using bladder cancer cell lines. We found that this 
combination decreased cell proliferation in a dose dependent manner in comparison to the 
chemotherapy agent alone namely in NMIBC.  
We also evaluated the correlation between the expression of PI3K/AKT/mTOR pathway 
activation and STn with tumoral progression and cachexia. 
Regarding PI3K/AKT/mTOR and bladder cancer-induced skeletal wasting we found that in rats, 
BBN induced urothelial carcinoma, there was 17% of body weight loss – cachexia; the reduced 
levels of pAKT, mTOR and p70S6K suggested the suppression of PI3K/AKT/mTOR pathway.  
Observing the correlation of STn in bladder tumours with tumour proliferation and clinical 
relevance we found that 75% of the high grade bladder tumours, expressing STn presented 
elevated proliferation rates and high risk of recurrence/progression. Thus STn expression 
correlated with cell invasive capability and was not expressed by the normal urothelial.  
Concerning Patient-derived tumour xenografts we studied the tumour model of bladder cancer 
preserving the original tumour identity. In the evaluation of the expression of tumour markers 
p53, p63, KI-67, CK20 and STn we found  similarities between the primary tumours and the 
xenografts although p53 and KI-67 levels of expression increased; STn expression even though 
decreased was preserved in xenografts reinforcing a STn positive xenograft model.  
In summary, our results showed the activation PI3K/AKT/mTOR pathway either in NMIBC and 
MIBC; this is a key pathway in bladder cancer carcinogenesis and mTOR inhibitors are 
determinant as potential drugs in bladder cancer with high efficacy and low cytotoxicity.  
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1.1 Bladder Cancer 
Bladder cancer is the second more common cancer of the urinary tract [Williams and Stein, 
2004] and the ninth most common cancer diagnosis worldwide [Ferlay et al, 2013; Kaufman et 
al, 2009; Ploeg et al, 2009]. In the United States of America and Western Europe the bladder 
cancer histological type, that represents 90% of all, is the urothelial (transitional) carcinoma 
[Dall’Era et al, 2012]. In other regions of the world, namely Middle East and Africa, the 
squamous cell carcinoma, represents the more frequent histological type of bladder cancer due 
to the prevalence of Schistosoma Heamatobium infections [Jemal et al, 2011]. 
Bladder cancer treatment varies with the age and stage disease of the patient: the high rate of 
recurrence and the repeated surgical interventions make the treatment one of the most 
expensive ones of solid tumours [Sievert et al, 2009; Jacobs et al, 2010].  
Thus, bladder cancer is a serious public health problem, either by its prevalence, mortality, 
impact in the quality of life of families and patients as well as by its social-economic impact [Li 
et al, 2014; Klotz and Brausi, 2015]. 
1.1.1 Epidemiology and Etiology 
UCB is the seventh most common malignancy in men and seventeenth in women [Burger et al, 
2013]. An estimated number of 430 000 patients worldwide are diagnosed with bladder cancer 
annually, and more than 165 000 will die from this disease [Ye et al, 2014]. 
It affects primarily individuals of older age having a peak between 50 and 70 years in man. In 
the word, the rate of bladder cancer is about 3,5 in men to 1 woman [Shariat et al, 2010; Burger 
et al, 2013]. Although men are more likely to develop bladder cancer than women, women 
present with more advanced disease and have worse survival [Fajkovic et al, 2011]. 
Differences in the gender prevalence of bladder cancer may be due to several factors; it was 
proposed to be a result of different exposure to carcinogens, genetic factors, anatomic, 
hormonal and even social factors [Shariat et al, 2010; Fajkovic et al, 2011]. 
 11 
 
Bladder cancer incidence is variable between regions and countries: in the United States is the 
sixth most common cancer with an estimated 74,690 new cases to be diagnosed in 2014 
[Charlton et al, 2014]. In Europe is the fourth more common cancer in men and the eighth 
cause of death by cancer [Ferlay et al, 2010]. 
The highest and the lowest  incidence rates are found in the countries of Europe : the higher in 
Spain- 41,5 per 100000 habitants in men and 4,8 in woman, and the lowest in Finland – 18,1 in 
men and 4,3 in woman [Ferlay et al, 2010]. In Portugal, in 2008, there was an estimated of 1935 
new cases of bladder cancer with 721 deaths [RON, 2008]. According to national oncology 
records, in 2008, this disease was the fifth most common cancer type in men and tenth in women 
(Figure 1) [RON, 2008]. 
 
 
 
Bladder cancer (BC) is a disease of multifactor a aetiology, associated genetic susceptibility and 
gene–environment interactions, in which cigarette smoking is a major risk, responsible for half 
of the new cases in men and one third in woman [Wu et al, 2008; Chen et al, 2010]. Cigarette 
Figure 1: Most frequent tumours by gender, in 2008 (adapted from Roreno, 2008). 
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smoke is rich in aromatic amines and hydrocarbons that can form DNA adducts. The incidence 
of bladder cancer is directly related to the duration of smoking and the number of cigarettes 
smoked per day [Alberg et al, 2007]. 
An immediate decrease in the risk of bladder cancer was observed in those who stopped 
smoking. The reduction was about 40% within 1-4 years of quitting smoking and 60% after 25 
years of cessation, although ex-smokers are always in risk of developing the disease when 
compared with non- smoking population [Murta-Nascimento et al, 2007]. 
Occupational exposure to aromatic amines and chlorinated by products is the second most 
important risk factor for bladder cancer. Work-related cases have accounted for 20-25% of all 
bladder cancer cases, but this percentage in decreasing with the implementation of safety 
security hazard measures. This exposure is seen mainly in workers from the industrial area of 
transformation like dyes, rubbers, textiles, paints and leathers [Letasiová et al, 2012; Burger et 
al, 2013]. In the case of aromatic amines the risk of bladder cancer due to occupational 
exposure is significantly greater after 10 years or more of exposure and the mean latency 
period usually exceeds 30 years [Weistenhofer et al 2008; Harling et al, 2010]. The histological 
type usually associated with occupational exposure, is the urothelial or transitional bladder 
cancer [Tanaka, 2011]. 
In areas where chronic urothelium infection by Schistosoma haematobium is endemic, like 
Africa and Middle East , including Israel, Egypt, Syria, Iraqi and Iran, there is a high incidence of 
squamous cell bladder cancer [Santos et al, 2011]. 
Other chronic urinary tract infections have also been linked to the development of bladder 
cancer while pelvic radiotherapy and chemotherapy agents are associated with the 
development of secondary bladder malignancies. 
Several dietary factors have been considered to be related to bladder cancer ( 
Table 1); however, the links remains controversial; one of these is the consume of water 
containing arsenic and/or chlorinated products although the proper ingestion of fluids can 
reduce the exposure time to this carcinogens, dilute the urine and increase the urinating rate 
[Kirkali et al, 2005; Tanaka et al, 2011; Burger et al, 2013]. Age and genetic susceptibility are 
 13 
 
also associated risk factors for bladder cancer: this risk increases by two fold in first degree 
relatives of bladder cancer patients. Although there are many studies that identify genetic 
susceptibility loci for bladder cancer there are only ten validated, including N-acetyltransferase 
2 (NAT2) slow acetylator and glutathione S-transferase mu 1 (GSTM1)–null , two risk factors 
when combined with environment exposure to carcinogenic substances like cigarette smoke 
[Burger et al, 2013]. 
Table 1: Bladder cancer risk factors (adapted from Mitra and Cote, 2009) 
Risk factor Mechanism of carcinogenesis 
Primary cellular 
process(es) altered 
Strength of 
association 
Lifestyle 
Tobacco smoking Exposure to carcinogens in tobacco 
smoke, including aromatic amines, 
hydrocarbons, and tar 
Cell-cycle regulation, 
gene regulation 
Strong 
Hair dye use Exposure to aromatic amines Cell-cycle regulation Weak 
Occupation 
Dyestuff 
manufacturing 
Exposure to aromatic amines and 
aniline dyes 
Cell-cycle regulation, 
gene regulation 
Strong 
Rubber manufacturing Exposure to aromatic amines, 
aniline, and o-toluidine 
Cell-cycle regulation Strong 
Painting Exposure to aromatic amines and 
aniline dyes 
Cell-cycle regulation, 
gene regulation 
Moderate 
Leather processing Exposure to aromatic amines
  
Cell-cycle regulation Moderate 
Printing Exposure to aromatic amines and 
aniline dyes 
Cell-cycle regulation, 
gene regulation 
Weak 
Hairdressing Exposure to aromatic amines from 
hair dyes and gels 
Cell-cycle regulation Weak 
Aluminum smelting Exposure to polycyclic aromatic 
hydrocarbons 
Cell-cycle regulation Strong 
Asphalt paving Exposure to polycyclic aromatic 
hydrocarbons 
Cell-cycle regulation Inadequate 
Firefighting Exposure to aromatic amines and 
polycyclic aromatic hydrocarbons 
Cell-cycle regulation Weak 
Truck driving Exposure to diesel exhaust Cell-cycle regulation Moderate 
Diet 
Chlorine and 
chlorination by-
Direct carcinogenic effect Unconfirmed Moderate 
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products (in drinking 
water) 
Arsenic (in drinking 
water) 
Direct carcinogenic effect Cell-cycle regulation, 
signal transduction, 
gene regulation 
Strong 
Coffee Carcinogenic metabolites from 
caffeine in the urine 
Unconfirmed Inadequate 
Artificial sweeteners Unknown in humans Unconfirmed Inadequate 
Drugs and therapies 
Phenacetin, 
cyclophosphamide, 
pelvic irradiation 
Induction of DNA fragmentation Gene regulation Moderate 
Urologic pathologies 
Schistosoma 
haematobium 
Exposure to toxins and N-
nitrosamines 
Gene regulation Strong 
Cystitis or other 
urinary tract infection 
Chronic inflammation Cell-cycle regulation, cell 
death, gene regulation 
Moderate 
Urinary calculi Chronic inflammation Cell-cycle regulation, cell 
death, gene regulation 
Weak 
Ancestry and genetics 
Family history Genetic predisposition Depends on the genetic 
alteration(s) 
Strong 
NAT2 polymorphism Inefficient detoxification of 
aromatic amines 
Gene regulation Strong 
NAT1 polymorphism Promotion of formation of DNA 
adducts of aromatic amines 
Gene regulation Inadequate 
GSTM1 Inefficient detoxification of 
carcinogens 
Gene regulation Weak 
 
1.1.2 Symptoms and diagnosis of bladder cancer 
The majority of patients diagnosed with BC present painless and visible hematuria. Symptoms 
of bladder irritation like increased rate of urinary frequency occur mainly in patients with 
carcinoma in situ (CIS). The obstructive symptoms occur when the tumour is near the urethra. 
In advanced disease, patients present lumbar pain, edema of the lower limbs, pelvic palpable 
mass, weight loss, and bone pain from distant metastasis, however this symptoms almost never 
occur without a previous story of hematuria [Sharma et al, 2009; Urquidi et al, 2012]. 
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The clinical investigation should begin with a careful history, including any history of cigarette 
smoking or occupational exposures. Patients with urinary symptoms should have a urinalysis 
with urine microscopy and a urine culture to rule out infection [Sharma et al, 2009]. Urine 
Cytology and also Cystoscopy can be used for diagnosis of bladder cancer [Sharma et al, 2009; 
Latini et al, 2010]. Urine cytology is a non-invasive test for the diagnosis of bladder cancer with 
a high specificity but a low sensitivity mainly in low grade bladder tumours. This method is 
more specific for high grade tumours or CIS while cistoscopy is effective for papillar tumours 
diagnosis [Sharma et al, 2009; Ye et al, 2014]. 
In the recent years there was a development in noninvasive screening tools for bladder cancer, 
including tumour associated antigens, proliferative antigens, oncogenes, peptide growth factors 
and its receptors, adhesion molecules, tumoral angiogenesis markers and its inhibitors and cell 
cycle regulatory proteins. Clinical routine use of this tests was already aproved by the Food and 
Drug Administation (FDA), however while the tests present a higher sensibility than cytology, a 
few have the same specificity (Table 2) [Urquidi et al, 2012; Wadhwa et al,2012; Ye et al, 2014].  
 
Table 2: Urine biomarkers for detection and surveillance of bladder cancer (adapted from Ye et al, 2014) 
Test Markers Sensitivity* Specificity* 
BladderCheck (point-of-care) and 
Bladder Cancer Test 
NMP22 34 – 95% 55-85% 
Cytology Urothelial cells 30 – 92% 93 – 97% 
ImmunoCyt 
Urothelial cell and 
immunostain 
55 – 90% 33 – 87% 
Urovysion FISH 51 – 92% 55 – 95% 
BTA stat (point-of-care) and BTA-
TRAK 
Bladder Tumor Antigen 36 – 91% 50 – 90% 
ACCU-DX (point-of-care) FDP 60 – 83% 80 – 86% 
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1.1.3 Histological classification, stage, and grade of bladder cancer  
Bladder cancer can be classified histologically as urothelial or non-urothelial; 90% of the cases 
are urothelial in developing countries and the remaining 10 % are non-urothelial or 
undifferentiated (Table 3) [Sharma et al,2009; Kaufman et al,2009; Vishnu et al, 2011].  
 
Table 3: Bladder cancer classification (adapted from Sharma et al, 2009) 
Epithelial neoplasms 
Urothelial (transitional cell) 
    neoplasms (90%) 
    Papilloma 
        Flat 
        Papillary 
    Papillary urothelial carcinoma 
        Low malignant potencial 
        Low – grade 
        High – grade 
    Invasive urothelial carcinoma 
        Lamina propria invasion 
        Muscularis própria (detrusor muscle 
        invasion 
Nonurothelial neoplasms  
    (9%) 
    Squamous cell carcinoma 
        Verrucous carcinoma 
    Adenocarcinoma 
        Clear cell 
        Hepatoid 
        Nonurachal 
        Signet ring cell 
        Urachal 
Small cell carcinoma 
Rare neoplasms 
    Basaloid squamous cell 
        carcinoma 
    Carcinoid tumour 
    Lymphoepithelial 
        carcinoma 
    Melanoma 
Nonepithelial 
    (mesenchymal) 
    neoplasms (1%) 
Benign 
    Hemangioma 
    Leiomyoma 
    Lipoma 
    Neurofibroma 
    Paraganglioma 
Malignant 
    Angiosarcoma 
    Leiomyosarcoma 
    Malignant fibrous 
        histiocytoma 
    Osteosarcoma 
    Rhabdomyosarcoma 
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The staging system used in bladder cancer is called TNM, which stands for tumour, node, 
metastasis (TNM system; Table 4) [Greene 2002; Edge, 2010]. This system staging is based on 
the growth of the tumour into the bladder and the deep of invasion. The NMIBC include the 
urothelium carcinomas of papillar morphology (Ta) flat tumours (Tis, in situ) and lamina propria 
infiltrating lesions (T1). When the tumour invades the lamina propria the stage is classified 
according with the deep of muscle invasion (T2a, T2b). If the tumour invades the surrounding 
connective tissue the stage is T3 (T3a, T3b). In the T4 stage the tumour has spread to the 
adjacent structures of the bladder [Chen et al, 2009; Edge, 2010]. 
 
Table 4: TNM System - American Joint Committee on cancer for Bladder cancer (adapted from Sharma et   
al, 2009) 
 
 
 
 
 
 
 
 
 
 
The histological grade is established according to the cellular characteristics being an important 
risk factor to disease progression in NMIBC [Knowles and Hurst, 2015]. Recently, there are used 
2 systems of classification: the one from 1973 of the World Health Organization (WHO) and the 
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Figure 2: Stage and Grade of BC. A) Stage of bladder cancer according to TNM system B) Histological 
Grade classification according the WHO 1973, and the ISUP 2004 (adapted from Knowles and Hurst, 
2015) 
one from 2004 from WHO/International Society of Urological Pathology (ISUP) [Babjuk et al, 
2013]. 
The major difference is the classification of the tumours of papillar morphology that are 
classified as grade 1, 2 and 3 in the old system and in the 2004 classification correspond to an 
urothelial lesion of low-grade malignant potential, (same as grade 1; papillary urothelial 
malignancy of low malignant potential – PUNLMP), urothelial papillary of low grade and 
urothelial papillary high grade carcinoma (Figure 2: Stage and Grade of BC. A) Stage of bladder 
cancer according to TNM system B) Histological Grade classification according the WHO 1973, 
and the ISUP 2004 (adapted from Knowles and Hurst, 2015) [Babjuk et al, 2013]. 
 
To classify the risk of NMICB the European Association of Urology (EUA) divides the patients in 
low, medium and high risk of bladder cancer recurrence, that require different treatment 
approaches. The low risk is defined as a primary tumour, unique, Ta of low grade; medium risk 
is defined as multiple tumours of low grade; high risk any tumour T1 and/or CIS and multiple 
recurrent tumours over 3 cm. This stratification is based on clinical and pathological factors, 
tumour stage and grade, multifocality, size of the tumour, frequency of recurrence after 
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transurethral resection (TUR), and presence of CIS (Figure 2) [Colombel et al, 2008; Bellmunt, 
2011; Babjuk et al, 2013]. 
The biologic behaviour and clinical phenotype of NMIBC and MIBC arises from two distinct 
oncogenic pathways [Tanaka et al, 2011]. The low grade tumours always of papillary 
morphology and generally superficial, or non-muscle-invasive (NMI), represent 70-80% of the 
BC. This tumours are frequently multifocused with 50-70% recurrence, but normally don’t 
progress and the overall 5 years survival is of 90%. Genetic instability is the key to the 
accumulation of genetic alterations needed for tumour progression, and in a small percentage 
(10-15%) these ones can evolve to invasive tumours. It’s thought that urothelial hyperplasia is 
the precursor lesion of this variant. The remaining UBC (about 20%) are diagnosed as high 
grade, frequently non-papillary, invasive or with metastatic disease. The major reduction seen 
in overall survival (OS) of these patients, especially due to metastasis, makes these tumours the 
major responsible by the mortality rates in BC with an OS less than 50%, at 5 years. This variant 
seems to emerge de novo or derives from CIS, and precedes urothelial dysplasia (Figure 3). 
Many patients that initially present superficial papillary tumours of low grade can develop in 
the adjacent mucosa CIS [Wu et al, 2008; Knowles, 2008; Kaufman et al, 2009; Hodges et al, 
2010; Knowles et al, 2014]. 
The genetic alterations that occur in the NMIBC involve the genes Fibroblast Growth Factor 
Receptor 3 (FGFR3), Harvey Rat Sarcoma Viral Oncogene Homolog (H-RAS) and PIK3CA [Turo et 
al, 2014; Liu et al, 2014]. The other oncogenic pathway of the MIBC presents alterations in 
several tumoral suppressor genes involved in cell cycle control namely p53, p16 and 
retinoblastoma (RB) (Figure 3) [Jacobs et al, 2010; Netto et al, 2013 Turo et al, 2015; Liu et al, 
2014]. 
The first genetic alterations observed in both oncogenic pathways of BC are in chromosome 9, 
promoting genetic instability and leading to accumulation of genetic defects. Other 
chromosomal alterations functional and numerical, associated with BC show some potential 
both in diagnosis and prognosis namely gains in chromosome 3q, 7p and 17q  and deletion of 
the 9p21 (Figure 3) [Hartmann et al, 2002; Netto et al, 2013; Knowles and Hurst, 2015]. 
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1.1.4 Treatment 
Bladder cancer have significant heterogeneity whether in pathology or response to therapeutic 
or survival, driving new strategies of research and selection of the best treatments [Kaufman et 
al, 2009]. Optimal treatment is multidisciplinary, involving urology, pathology, and oncology 
and after diagnosis a close follow-up is essential [Sharma et al, 2009]. 
Concerning NMIBC (Ta and T1) the usual treatment is a complete eradication of the tumour by 
TUR including part of the adjacent muscle. A second TUR should be considered when the initial 
one is incomplete, in tumours of high grade and /or T1 due to the risk of progression by the 
residual tumour [Babjuk et al, 2013]. In this group the problem is the high rate of recurrence 
and progression to a stage that invades the muscle layer, so it is combined with intravesical 
adjuvant therapies. The patient selection is based in the associated pathological risks: tumour 
stage and grade, multifocality, tumour size, presence of CIS and recurrence frequency after TUR 
[Jacobs et al, 2010; Babjuk et al, 2013]. The intravesical Bacille Calmette-Guérin (BCG) and 
Figure 3: Divergent Oncogenic pathways in bladder cancer. Potential pathogenesis pathways are shown 
based on histopathological and molecular observations (adapted from Knowles and Hurst, 2015). 
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agents like mitomycin and epirrubicine are frequently used from intravesical therapy. It is 
recommended to all tumours of the bladder with a recent diagnosis a single intravesical 
instillation in the first 24h after the TUR [Griffiths et al, 2012]. The BCG therapy is applied in 
patients with CIS and recurrent superficial tumours, and the answer to this treatment with BCG 
or chemotherapy is an important prognostic factor in progression and death caused by BC 
[Sharma et al, 2009; Babjuck et al, 2013]. The TUR followed by intravesical BCG once a week 
during 6 weeks is recommended for CIS [Sharma et al, 2009]. 
Radical cystectomy (RC) should be considered in the NMIBC of high risk like recurrent tumours, 
T1 of high grade or CIS, in the BCG refractory tumours or in tumours of large size difficult to 
remove by TUR [Cheung et al, 2013]. Although BCG treatment has secondary effects its efficacy 
in BC recurrence prevention is higher than other chemotherapies [Jacobs et al, 2010]. In this 
group of tumours is difficult to define a treatment to apply in patients with high risk of 
recurrence and progression to advanced disease stages [Babjuck et al, 2013; Kaufman et al, 
2009; Kulkarni et al, 2007]. 
The MIBC, as referred above is an aggressive carcinoma with a bad prognostic and the main 
cause of morbidity and mortality by BC. The standard treatment for this BC group is RC with 
pelvic lymphadenectomy. In men RC involves cystoprostatectomy and cystectomy, usually with 
hysterectomy in women, followed by a urinary diversion procedure. Patients with metastatic 
disease are also treated with chemotherapy [Sharma et al, 2009; Jacobs et al, 2010].  
It is expected that the patients receiving adjuvant chemotherapy have 14 months of mean 
survival expectancy while patients without treatment only have 8 months. About half of the 
patients subjected to RC are going to recur and die of metastatic disease [Youssef et al, 2009; 
Guancial et al, 2015]. 
In the last 30 years, standard treatment is neoadjuvant and adjuvant chemotherapy combining 
gemcitabine and cisplatin. Cisplatin is a cytotoxic agent vastly used in BC, with an answer rate of 
50-70% although with no recurrence OS of 8 months. In patients with extensive comorbid 
diseases, they have the carboplatin, which shows a global decreased response compared with 
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cisplatin [Teply and Kim, 2014]. Carboplatin-based regimens are well tolerated and used in 
patients with insufficient renal reserve [Sharma et al, 2009; Teply and Kim, 2014]. 
Combination of gemcitabine and cisplatin is the standard treatment for most patients because 
of its lower toxicity. Combination methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) 
has comparable effectiveness to gemcitabine/cisplatin; however, toxicity limits its use [Jacobs 
et al, 2010]. 
There is no therapeutic agents of second line FDA approved, although in Europe vinflunine, an 
alcaloide, is approved, remaining the only option for second line chemotherapy in metastatic 
patients after cisplatin based treatment [Gallagher et al, 2008; Guancial et al, 2015]. Thus, BC is 
a chemotherapy sensitive carcinoma the OS of a patient with metastatic disease is 
approximately 15 months [Milowsky et al, 2013]. 
It is urgent to stratify the patients, improving the actual treatment options, and also to develop 
new therapeutic targets to prevent or delay disease progression, improving the life quality of 
these patients and survival. Figure 4 summarizes the symptoms, diagnosis and treatment of BC. 
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Figure 4: Symptoms, diagnosis and management of BC. Red boxes represent areas of ongoing 
investigation and clinical trials (adapted Cross and Whelan, 2010). 
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1.2 Bladder cancer and skeletal muscle wasting 
Weight loss in cancer patient is very common especially in advanced stages being responsible 
for 25-30% of cancer related deaths [Bonetto et al, 2011]. Cancer caquexia is associated with a 
reduction in treatment tolerance, response to therapy, quality of life and survival [Jonhs et al, 
2014]. The incidence and severity of caquexia is dependent of the tumour type, site and mass 
and also of the reduced food intake [Tisdale, 1997]. Such abnormal metabolism varies 
according to the individual and the stage of the disease, also specific effects of the tumour like 
bowel obstruction and existing morbidities leads to the development of caquexia. There are 
several mechanisms underlying tumor-host interaction resulting in the abnormal metabolism 
such as activation of proteolytic pathways preceding pro-inflammatory cytokines production 
and more recently myostatin expression – a member of the TGF-β. Intracellular signaling 
pathways leading to myostatin expression are not fully understood. Myostatin increases muscle 
protein degradation through the proteolytic ubiquitin system and others. Protein degradation is 
mediated by complex systems namely by PI3K/AKT pathway [McFarlane et al, 2006]. 
Patients with gastric or pancreatic cancer have the highest frequency of weight loss [Tisdale, 
2009]. There is a need for the better understanding of the process underlying cancer-induced 
skeletal muscle wasting as a key point to improve the therapeutic strategies [Padrão et al, 
2013]. 
1.3 mTOR Signalization pathway 
The Mammalian Target of Rapamycin (mTOR), a downstream mediator in the phosphoinositide 
3-kinase (PI3K)/Akt signaling pathway, plays an important role in the regulation of cell 
metabolism, growth, proliferation and survival. In particular mTOR is a key protein kinase by 
monitoring nutrient availability, cellular energy levels, oxygen levels, and mitogenic signals [Liu 
et al, 2009; Laplante and Sabatini, 2009]. Signaling through mTOR is activated by amino acids, 
insulin, and growth factors, and impaired by nutrient or energy deficiency. In normal cells 
mTOR plays a key role in cell physiology, homeostasis and regulates numerous components 
involved in protein synthesis, including initiation and elongation factors, and the biogenesis of 
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ribosomes [Bjornsti and Houghton, 2004; Dutcher, 2004]. In several diseases and mainly in 
cancer, this capacity is lost; mutations and continuous activation of this pathway leads to a 
persistent proliferation and tumour growth [Cheng et al, 2013]. Aberrant activation of the 
mTOR pathway has been widely implicated in many cancers, and increased activity of this 
pathway is often associated with resistance to cancer therapies, for this reasons it is a 
promising target for anti-cancer therapies [Fasolo and Sessa, 2012]. This fact was the basis to 
the development of new targeted therapies, and several have progressed to clinical trials with 
some success. In recent studies combinational strategies have emerged to overcome resistance 
to mTOR targeting and enhance their efficacy [Guancial and Rosenberg, 2015]. In several cancer 
types like renal cell carcinoma and breast cancer rapamycin analogs (rapalogs) have shown 
some clinical efficacy, although we need more studies exploring the antitumor activity of mTOR 
targeting-drugs [Motzer et al, 2008; Amato et al, 2013; Vicier et al, 2014]. Besides the 
limitations of rapamycin-based therapies in the clinical setting led to the development of a 
second generation of anti-mTOR drugs with substantial  improvement of anti-tumor activity 
both in vitro and in animal-models [Moscheta et al, 2014]. 
1.3.1 The mTOR pathway 
mTOR is the target of rapamycin,  a macrolide produced by Streptomyces Hygroscopius bacteria 
and known by its anti-proliferative properties [Cafferkey et al, 1993; Sabatini et al, 1994]. In the 
early 1990s, the mTOR was identified and cloned shortly after the discovery of the two yeast 
genes TOR1 and TOR2, in budding yeast Saccharomyces cerevisiae during a screen for 
resistance and toxicity of rapamycin [Sabatini et al, 1994; Sabers et al, 1995]. To date, every 
eukaryote genome examined including mammals contains a TOR gene [Bjornsti and Houghton, 
2004; Pópulo et al, 2012]. 
FRAP (FKBP12-rapamycin-associated protein), RAFT1 (rapamycin and FKBP12 target), RAPT 1 
(rapamycin target 1), or SEP (sirolimus effector protein), also known as mTOR, is a 
serine/threonine kinase of 289 KDa that belongs to the PI3K-related protein Kinase (PIKKs) 
family, since its C-terminus shares strong homology to the catalytic domain of PI3K [Bjornsti 
and Houghton, 2004; Vignot et al, 2005]. There are two tandem repeated HEAT motifs (protein 
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interaction domains in the N-terminus of mTOR found in Huntington, Elongation factor 3, 
PR65/A and TOR), followed by a FAT domain (domain shared by FRAP, Ataxia telangiectasia 
mutated, and TRRAP. These factors are PIKK family members), a FRB domain (FKBP12-
rapamycin-binding site, found in all eukaryotic TOR orthologs), a PtdIns 3-kinase related 
catalytic domain, an auto-inhibitory domain (repressor domain or RD domain), and a FATC 
domain (FAT C terminus)- this last one located at the C-terminus of the protein. The FRB 
domain forms a deep hydrophobic cleft that serves as the high-affinity binding site for the 
inhibitory complex FKBP12-rapamycin (Figure 5) [Hay and Sonenberg, 2004; Yang et al, 2007; 
Martelli et al 2010]. 
Figure 5: A schematic presentation of mTOR domain structure. (Adapted from Pópulo et al, 2012) 
 
mTOR assembles into two distinct complexes named mTOR complex 1 (mTORC1) and 2 
(mTORC2) with different sensitivities to rapamycin as well as upstream inputs and downstream 
outputs [Zoncu et al 2011; Laplante and Sabatini, 2012]. 
The mTORC1 is sensitive and mTORC2 is considered resistant to rapamicin. However, Sarbassov 
and colleagues, shown that long-term treatment with rapamycin can disrupt mTORC2 assembly 
and function by sequestering newly synthesized mTOR molecules [Sarbassov et al 2006]. 
mTORC1 is composed of mTOR, raptor, mLST8, and two negative regulators, PRAS40 and 
DEPTOR [Efeyan et al, 2012; Lamming et al, 2013]. 
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Raptor is a protein of 150Kda with a terminal amino region highly conserved followed by 
several HEAT repeats and seven carboxyterminal WD40 repeats. A knockout of raptor indicates 
that it functions in mTOR signaling acting as an adaptor to recruit substrates to mTOR. 
Alternatively other studies show that raptor negatively regulates mTOR when bound to the 
kinase. So it remains controversial if raptor is a positive or negative regulator of mtor, though is 
indispensable for mTOR phosphorilation of S6K1 and 4EBP1proteins [Yang and Guan, 2007; 
Chiong and Esuvaranathan, 2010]. 
mLST8 is a 36KDa protein identified after raptor and it contains seven WD40 repeats. Knockout 
studies both in mammals and yeast suggest that mLST8 regulates positively mTORC1 signaling; 
other authors also suggest a role of mLST8 in mTORC2. It is believed that this protein is 
necessary for the full catalytic activity of TOR [Guertin and sabatini, 2007; Yang and Guan, 2007; 
Zoncu et al, 2011]. 
PRAS40 a proline-rich Akt substrate of 40kDa is a very important component of mTORC1 
inhibiting its activity via RAPTOR; thus it links the Akt and the mTOR pathways [Guertin and 
Sabatini, 2007]. 
 The protein DEPTOR, with 48 kDa, was recently described and it binds to mTOR inhibiting this 
kinase within TORC1 and TORC2 complexes [Peterson et al, 2009; Laplante and Sabatini, 2012].  
The mTORC2 comprises six different proteins, several of which are common to mTORC1 and 
mTORC2: mTOR; rapamycin-insensitive companion of mTOR (Rictor); mammalian stress-
activated protein kinase interacting protein (mSIN1); protein observed with Rictor-1 (Protor-1); 
mLST8; and Deptor [Efeyan et al, 2012; Lamming et al, 2013].  
Rictor is a large protein of 200 KDa unique to mTORC2 Knockdown of rictor results in loss of 
actin polymerization and cell spreading [Chiong and Esuvaranathan, 2010]. 
There is some evidence that mSIN1 and Rictor stabilize each other, establishing the structural 
foundation of mTORC2. Rictor also interacts with Protor-1, but the physiological function of this 
interaction is not clear. mLST8 is essential for mTORC2 function and Deptor negatively regulates 
mTORC2 activity [Sengupta et al, 2010; Huang and Fingar, 2014]. 
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mTORC1 responds to amino acids, stress, oxygen, energy, and growth factors allowing cell 
growth by inducing and inhibiting anabolic and catabolic processes, respectively, and also drives 
cell-cycle progression. mTORC2 responds to growth factors and regulates cell survival and 
metabolism, as well as the cytoskeleton, it is insensitive to acute rapamycin treatment but 
chronic exposure to the drug can disrupt its structure (Figure 6) [Wullschleger et al, 2006; 
Laplante and Sabatini, 2012]. 
 
1.3.2 Upstream and downstream mTOR pathway regulation  
mTOR is only one part of the larger phosphoinositide 3-kinase (PI3K)/AKT/mTOR pathway. This 
pathway is activated, upstream, by growth factors, such as insulin, mitogens, hormones or 
nutrients, that activate PI3K in the cell membrane.  PI3K is a heterodimer that consists of a 
catalytic subunit (p110) and a regulatory subunit (p85, p55, or p50) [Porta et al, 2014, 
Zarogoulidis et al, 2014]. The activated p110 catalytic subunit, encoded by the PIK3CA gene, 
phosphorylates phosphatidylinositol bisphosphate 4, 5 on the inner leaflet of the cytoplasmic 
membrane to generate phosphatidylinositol triphosphate (PIP3). The mTOR and this lipid 
products are involved in a number of cellular processes including cell proliferation, survival, 
cytoskeletal reorganization, membrane trafficking, cell adhesion, motility, angiogenesis and 
insulin action [Willems et al, 2012]. The binding of insulin to the cell surface receptor causes the 
Figure 6: mTORC1 and mTORC2 cross regulation and cell dynamics (adapated from Laplante 
and abatini, 2012). 
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insulin receptor activation with recruitment of insulin receptor substrate 1 (IRS1) and the 
production of PIP3 though the activation of PI3K [Sarbassov et al, 2005].       
PIP3 recruits Akt to the plasma membrane where it is phosphorylated and activated by 
phosphoinositide-dependent kinase-1 (PDK-1) and mTORC2 [Hay and Sonenberg, 2004; 
Sarbassov et al, 2005]. 
The best studied downstream substrate of AKT is the serine/treonine Kinase mTOR. AKT can 
directly phosphorylate and activate mTOR, as well as cause indirect activation of mTOR by 
phosphorylating and inactivating TSC2 (tuberous sclerosis complex 2), which normally inhibits 
mTOR through the GTP-binding protein Rheb (Ras homolog enriched in brain). When TSC2 is 
inactivated by phosphorylation, the GTPase Rheb is maintained in its GTP-bound state, allowing 
for increased activation of mTOR [Hay, 2005]. 
Activated mTOR can subsequently phosphorylate downstream effectors S6K1 (p70 ribossomal 
protein S6 Kinase 1) and 4EBP1 (eIF4E binding protein) [Ching and Hansel, 2010]. On clinically 
healthy conditions, S6K1 and 4EBP1 are bound to eIF3 (eukaryotic initiation factor 3) remaining 
inactive. With growth stimulations, mTOR binds to eIF3 and phosphorylates S6K1 and 4EBP1. 
The phosphorylation of S6K1 releases it from eIF3 and activates the kinase. S6K1  activation 
promotes translation of mRNAs and growth by phosphorylating cellular substrates, such as S6 
[Bjornsti and Houghton, 2004; Pópulo et al, 2012]. When 4EBP1 binds to translation initiator 
eIF4E (eukaryotic translation initiation factor 4E) it inhibits cap-dependent mRNA translation. 
mTOR phosphorylates 4EBP1, and the phosphorylation of 4EBP1 frees it from eIF4E, relieving its 
inhibitory effect and stimulating translation initiation. Active mTOR enhances cell growth by 
promoting protein translation and increasing cell mass [Bjornsti and Houghton, 2004; Inoki et 
al, 2005; Sarbassov et al, 2005]. 
The inhibition of mTOR by rapamycin also causes 4EBP1 dephophosrilation which prevents 
protein translation. There is evidence of a negative feedback loop from the mTOR-S6K1 
pathway to the upstream IRS pathway. Activation of mTORC1 and S6K1 regulates IRS-1 leading 
to a negative feedback regulation of both PI3K and MAPK signaling pathways. In some tumours 
activation of mTORC1 may be PI3K independent [Moschetta et al, 2014]. 
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 mTORC2 upstream regulates are less known although studies show that direct association with 
ribossome is required for mTORC2 activation – event in the dependence of PI3K activity 
[Carracedo et al, 2008]. This mTORC2 upstream regulatory mechanism shows the link between 
the two mTOR complexes: mTORC2 promotes mTORC1 activity via the AKT-TSC1/TSC2 pathway 
and in return mTORC1 controls mTORC2 activity through of ribossomal biogenesis [willems et al 
2012].  
The central negative regulator of PI3K/AKT/mTOR signaling cascade is phosphatase and tensin 
homolog deleted on chromosome 10 (PTEN) which was first discovered in 1997 as a 
phosphatase, that is mutated or lost in several cancers [Liaw et al 1997]. Located on 
chromosome 10q23, PTEN is a multifunctional phosphatase whose major substrate is 
phosphatidylinositol-3,4,5-triphosphate (PIP3), which is a second messenger molecule 
produced following class I phosphoinositide 3-kinases (PI3K) activation in response to various 
growth factors [Sansal and Sellers, 2004]. Cytoplasmic PTEN negatively regulates this pathway 
by dephosphorylating PIP3 at its D3 position, thereby inhibiting downstream kinase activation 
and preventing cancer cell growth and survival. In contrast, nuclear PTEN exhibits phosphatase-
independent tumor suppressive functions, including regulation of chromosome stability, DNA 
repair, and apoptosis. The loss of PTEN is implicated in the loss of integrity of the genome 
[Ching and Hansel, 2010]. 
 
1.3.3 Bladder Cancer and the mTOR pathway 
As stated before the mTOR pathway is determinant for cell growth and proliferation and 
disruption of this pathway can result in altered cell dynamics and tumour development. 
Alterations in this pathway are common of several malignant diseases including melanoma, 
prostate cancer, renal cell cancer, breast cancer and others. Increased activity of this pathway 
can potentially promote tumorigenesis.  
There is evidence that elements in this pathway play an important role in this oncogenesis of 
bladder cancer, although there is little and inconsistent results about mTOR pathway activation 
in bladder tumour tissue; previous studies were performed using cell culture or animal models 
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but its clinical relevance remains uncertain. Previous studies of Hansel and colleagues showed 
74% expression of pmTOR in MIBC and a significant association with increased pathological 
stages and reduced disease-specific survival [Hansel et al, 2010]. Also Makhlin et al (2011) 
found pmTOR expression increased in malignant versus normal urothelium – 32% of tumours 
but with no association with clinical pathological stage. On the other hand there are other 
studies that showed that expression of mTOR is not increased when comparing with benign 
urothelium [Park et al, 2011]. This pattern of mTOR expression was also described in studies of 
Afonso and colleagues: 20% of tumour samples score positive for pmTOR expression when 
comparing with normal urothelium [Afonso et al, 2014]. mTOR expression was frequently 
observed but without stronger intensity in MIBC. Most of these studies are focused on patient 
with muscle invasive disease. 
Other molecular alterations of PI3K/AKT/mTOR pathway effectors have been reported in UBC 
including PTEN deletions, PTEN mutations, TSC1 inactivating mutation, and activations 
mutations of PIK3CA. Mutations in PIK3CA gene associate with increased mTOR signaling and 
bladder cancer cells resistance to apoptosis [Ching and Hansel, 2010]. Also PI3K pathway 
inhibition reduces the invasive capacity of bladder cancer. Several studies show a decrease or 
loss in PTEN expression which is associated with aggressive tumor growth, metastases and 
worsened patient outcomes. In superficial tumours PTEN loss is about 6, 6%, whereas in 
invasive tumours goes up to 30% [Wu et al, 2004; Ching and Hansel, 2010]. Chaux and 
colleagues when studying superficial tumors observed high levels of PTEN expression 
associated with higher rates of tumor recurrence, tumor progression and systemic metastasis 
[Chaux et al, 2013].  
Regarding pAKT expression, in more than half of UBC its higher expression suggested to 
contribute to invasion [Wu et al, 2004].  Also, there are different staining patterns (nuclear and 
cytoplasmic) in pAKT expression. Although AKT and pAKT levels are not significantly associated 
with tumor grade or stage [Sun et al, 2011].  
In MIBC mTOR pathway is commonly activated though PI3K mutations and inactivation of PTEN 
and TSC1: 21% demonstrate PI3K mutations, 30% demonstrate evidence of PTEN inactivation. 
 32 
 
Also 16% of patients have inactivating mutation in TSC1 [Ching and Hansel, 2010; Kompier et al, 
2010].  pS6 expression was observed in  55% of this BC cancer group [Hansel et al, 2010].  
1.3.4  mTOR pathway inhibitors in cancer therapy 
The mTOR inhibitors are divided in two groups: rapamycin/rapamycin analogs ou rapalogs and 
mTOR Kinase inhibitors [Macarulla et al, 2009]. Rapamycin, an immunosupressive drug also 
named sirolimus is a natural compound approved by FDA in 1999 for transplant rejection 
prevention [Huang and Houghton 2001; Fantus and Thomson, 2015]. Later studies found that 
its anti-proliferative properties could be used as a key agent in different tumour types, such as 
small cell lung cancer, breast, pancreatic, prostate cancer, osteossarcoma and B-cell-lymphoma 
[Muthukkumar et al, 1995; Seufferlein and Rozengurt, 1996; Grewe et al, 1999; Pang and Faber, 
2001; van der Poel et al, 2003]. Nowadays, due to limitations in the solubility and 
pharmacokinetic properties of rapamycin several derivatives have emerged including rapalogs 
temsirolimus, everolimus and deferolimus. The rapalogs either alone or combined are currently 
being evaluated in clinical trials as bladder cancer treatments [Zaytseva et al, 2012; Moschetta, 
2014].  
The second generation of mTOR inhibitors are known as ATP-Competitive mTOR kinase 
inhibitors (TKIs). TKI targets the mTOR kinase domain inhibiting the catalytic activity of mTORC1 
and mTORC2 with the advantage of minimizing the feed-back activation of PI3K/AKT, example 
Torin 1, PP30, PP242, Ku-0063794, AZD8055 and WYE-354 [Zaytseva et al, 2012].  
Also dual PI3K/mTOR inhibitors are being used in clinical trials including NVP-BEZ 235, XL-735 
and PI-103 (Figura 7) [Zask et al, 2011; Zaytseva et al, 2012].  
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Several compounds referred before are in clinical development as emerging therapeutic targets 
in bladder cancer. Everolimus has been investigated in a phase II study in pretreated metastatic 
urothelial tumors. The primary endpoint of two month progression-free survival wasn´t met by 
everolimus [Milowsky et al, 2013]. Another trials with everolimus/temsirolimus in a similar 
patient population showed a limited efficacy with single-agent [Seront et al, 2012; Gerullis et al, 
2012]. There is in course a phase I/II trial of everolimus and intravesical gemcitabine in BCG-
refractory primary or secondary CIS of the bladder (NCT01259063). Another phase two trial is in 
course combining paclitaxel and cisplatin ineligible patient with advanced urothelial carcinoma 
(NCT0125136).  
Also there was a phase II trial of temsirolimus for patients with advanced bladder cancer with 
limited efficacy so others trails are in course combining tensirolimus or everolimus and 
gemcitabine/cisplatin. The dual mTOR inhibitors are also being investigated with promising 
Figure 7: The mTOR pathway as a therapeutic target and the ongoing clinical studies (adapted from 
Mochetta et al, 2014). 
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preclinical results showing synergistic anti-tumor effects with lapatinib [Becker et al, 2014]. The 
list ongoing trials of mTOR and PI3K inhibitor are reported in table 5.  
Table 5: Novel molecularly targeted agents for the PI3K/mTOR under evaluation in patients with bladder 
cancer 
Agent Description Trial ID number Phase Design 
     
Everolimus mTORC1 inhibitor NCT01259063 I/II Everolimus and intravesical gemcitabine 
in BCG-refractory primary or secondary 
carcinoma in situ of the bladder 
Everolimus mTORC1 inhibitor NCT01215136 II In combination with paclitaxel for 
cisplatin-ineligible patients with advanced 
urothelial carcinoma 
Temsirolimus mTORC1 inhibitor NCT01827943 II Second-line therapy for patients with 
advanced bladder cancer  
MLN0128 mTORC1/mTORC2 NCT01058707 I Oral chemotherapy of, MLN0128 in 
patients with recurrence or progression 
of urothelial cancer that is metastatic. 
NVP-BEZ235 PI3K/mTOR  Preclinical  
PF-04691502 PI3K/mTOR  Preclinical  
Buparlisib Pan-classI selective 
PI3K inhibitor 
NCT01551030 II Patients with metastatic TCC 
 
1.4 Cancer-associated sialyl-Tn antigen (STn) 
The sialyl-Tn (STn) antigen is a tumor associated carbohydrate antigen expressed by several 
human carcinomas and rarely expressed in normal tissues [Cao et al 1996]. STn is a short O-
glycan containing a sialic acid residue α2, 6-linked to GalNAcα-O-Ser/Thr. The biosynthesis of 
STn is mediated by a specific sialyltransferase termed ST6GalNAc I, which competes with O-
glycans elongating glycosyltransferases and prevents cancer cells from exhibiting longer O-
glycans [Julien et al, 2012].  
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Several studies show that aberrant glycosylation is a key point in cancer development and 
metastization [Reis et al, 2010]. There is an important role of O-glycans mainly in the 
attachment and invasion of cancer cells, thus changes in these molecules are determinant for 
cancer development [Brockhausen, 1999]. 
STn expression by cancer cells is associated with a poor prognostic and a decreased OS of the 
patients [Werther et al, 1996].  
The main focus of research until the last decade was the STn use as a marker for diagnosis and 
subsequently prognosis in cancer. The recent focus was the targeting of STn by immunotherapy 
strategies to treat cancers [Julien et al, 2012].  An example is the vaccine consisting of STn 
antigen epitopes to immunize breast cancer patients [Julien et al, 2001].  
STn is expressed in many human carcinomas like breast, ovarian, gastric, colon and also bladder 
cancer. In bladder tumours, it is mainly present in advanced stage cases, while absent from 
most low-grade superficial lesions [Ferreira et al, 2013]. Moreover, it is not expressed by the 
healthy urothelium, denoting a cancer-specific nature and favoring disease dissemination 
[Ferreira et al, 2013; Carrascal et al, 2014].  
STn antigen is frequently observed in areas of invasion of the basal and muscle layers, 
suggesting its association with cell migration and invasion. Though STn is part of a malignant 
bladder cancer phenotype, as previously observed for other carcinomas [Clement et al, 
2004; Julien et al, 2006; Ohno et al, 2006; Ozaki et al, 2012; Pinho et al, 2007].  
Based on this information, it should be interesting to evaluate the expression of STn and Tn 
antigen its precursor, and PI3K/Akt/mTOR pathway activation in bladder cancer.  
The possible existence of expression of STn and mTOR pathway activation in more advanced 
tumours of bladder could help to design a new strategy therapeutic. 
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1.5 Urinary bladder cancer cell lines and animal models in bladder cancer therapy 
Traditional cell lines established from patient tumors and adapted to proliferate in culture have 
been widely studied. In vitro assays are used in the preclinical development of new drugs to 
discover, validate and evaluate the potential of new agents [Monks et al, 1991]. For more than 
a half century, tumor cell lines served as a foundation for cancer research, they are easy to 
propagate and study under defined conditions. However, continuous passages and culture of 
cells in vitro selects the cells better adapted to thrive in plastic dishes and excludes the 
variables associated with tumor stroma and other tumor micro environmental factors [Gillet et 
al, 2013]. 
Several tumor models have been used in basic science studies and clinical trials to increase our 
understanding of molecular mechanisms underlying tumor initiation, progression, metastasis 
and chemoresistance. There has been a continuous search for an ideal model that would mimic 
the clonal origin of human tumors, their histopathology, the multistage process of 
carcinogenesis and progression and their clinical behavior. 
Animal models have been used in UBC to predict the development and preclinical evaluation of 
news strategies for bladder cancer treatment [Arentsen et al, 2009]. The use of chemically 
induced urinary bladder cancer models allowed the study of the different stages of 
carcinogenesis and progression. According to the literature rodents proven to be suitable for 
these kinds of studies [Palmeira et al, 2010]. Rats and mice don´t develop, under normal 
conditions, spontaneous urinary bladder tumors. The occurrence of non-neoplastic urothelial 
lesions, such as inflammation and hyperplasia are also uncommon in these species [Oliveira et 
al, 2006].   
More than three decades ago a rat model of urothelial carcinogenesis has been described, 
induced with N-butil-N-(4-hidroxibutil) nitrosamina (BBN) – a genotoxic carcinogen [Becci et al, 
1981; Oliveira et al, 2006]. Mice exposition to BBN in drinking water induces the development 
of preneoplastic and neoplastic lesions in the urothelium of rodents, namely hyperplasia, 
dysplasia, low and high-grade papillary UBC, CIS and MIBC [Oliveira et al, 2006 ]. 
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This well-established model reflects the environment in urothelial carcinoma and reproduces 
tumor-host interaction [Arentsen et al, 2009]. The main limitations of this model are the costs 
and the long experimental protocol. 
Patient derived tumor xenograft models (PDTXM) are obtained implanting human derived 
tumor cell into immunocompromised mice which do not reject human cells. The tumors 
growing in these animals derive directly from patient tumor samples with minimal manipulation 
and recapitulate the biological characteristics of the tumor of origin. These models have shown 
to retain the cellular structure and molecular markers of the original tumors and have high 
predictive power [Fichtner et al, 2004; Rubio-Viqueira and Hidalgo, 2009; Dong et al, 2010]. 
PDTXM are suitable to evaluate individually the effectiveness of anticancer drugs, providing not 
only an investigational platform but a potential therapeutic decision making tool [Hidalgo et al, 
2011]. 
Xenografts models are easy and low cost when compared to the genetic engineered models. 
PDTXM preserves original cells heterogeneity, tumor phenotype and malignant potential of 
human tumors. Subcutaneous bladder tumor models have been widely used because of the 
ease of assessing tumour growth kinetics and because the orthotopic model is technically more 
difficult [Johnson et al, 2001; Rubio-Viqueira and Hidalgo, 2009; Arentsen et al, 2009].  
The main limitations of this model are the long lag period before tumor growing and low take 
rate, especially in the first passage. The stroma and blood supply is provided by the host and 
the tumor is not growing in the organ of origin [Rosfjord et al, 2014; Wilding and Bodmer, 2014. 
At present the development of new mTOR inhibitors could be accessed in this type of animal 
model identifying new targets and treatment regimens that improve the OS of bladder cancer 
patients. 
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2 Aims of the study 
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At the initial diagnosis of bladder cancer, 70% of cases are diagnosed as non-muscle-invasive 
bladder cancer (NMIBC) and approximately 30% as muscle-invasive bladder cancer (MIBC) 
[Witjes et al, 2013]. Regarding NMIBC the problem stands in recurrence and progression, and in 
the MIBC the high morbidity and mortality. Although this bladder tumours are chemotherapy 
sensitive, with the current strategies, there are still patients that don`t respond to the 
treatment. There is urgency in the identification of biomarkers to assist prognostic and the 
development of more effective targeted therapeutics namely signalling pathways frequently 
altered and tumour antigen markers. 
A. There are evidence that PI3K/Akt/mTOR pathway proteins and STn expression may hold 
value for bladder cancer patient stratification. With that in mind we performed several 
studies with the following aims: 
 to evaluate the expression and PI3K/Akt/mTOR pathway activation and STn in bladder 
cancer at different stages; 
 to correlate PI3K/Akt/mTOR pathway proteins expression  (pAkt, pmTOR and pS6 e 
PTEN) with bladder cancer patient stratification; 
 to evaluate the regulation of PI3K/Akt/mTOR and activation of the ubiquin- proteosome 
pathways in bladder cancer- induced skeletal muscle wasting; 
 to correlate the regulation of PI3K/Akt/mTOR and the expression of STn in bladder 
tumours its correlation with tumour proliferation and clinical relevance. 
 
B. Recently it has been reported that mTOR inhibitors could have an important role to play in 
bladder-cancer treatment and may restore chemosensitivity in resistant tumours  
 to use murine chemically induced urothelial tumours treated with Sirolimus to assess 
the impact of mTOR inhibitors on cell protein expression; 
 we intend to assess RAD001's in vitro ability to enhance Cisplatin cytotoxicity in three 
human bladder-cancer cell lines representative of the bladder cancer heterogeneity. 
 
C. Patient-derived tumor xenografts (PDTXs) are said to accurately reflect the heterogeneity of 
human tumours. In the case of human bladder cancer, few studies are available featuring 
these models. Patient-derived tumour xenografts (PDTXs) have been shown to be a highly 
predictive model to test standard chemotherapy and for identification of tumour types that 
might benefit from new treatments in clinical trials  
 We intend to establish and characterize a direct PDTXs model suitable to study the 
characteristics and behaviour of human tumours, namely the response to specific 
chemotherapeutic agents; 
 41 
 
 We intend to develop a direct PDTXs non-human model conserving the STn expression, 
and use it to compare tumour response and resistance to drugs. 
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3 Scientific articles 
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3.1 PI3K/Akt/mTOR pathway activation and STn expression in bladder cancer.  
3.1.1 Paper I 
Abnormal protein glycosylation and activated PI3K/AKT/mTOR pathway: role in 
bladder cancer prognosis and targeted therapeutics. 
Costa C and Pereira S, Lima L, Peixoto A, Fernandes E, Neves D, Neves M, Gaiteiro C, Tavares A, 
Gil da Costa R, Cruz R, Amaro T, Oliveira P, Ferreira A and Santos L. 
Article accepted for publication in the journal PLOS ONE 
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3.1.1 Paper II 
Bladder cancer-induced skeletal muscle wasting: disclosing the role of mitochondria 
plasticity. 
Padrão AI, Oliveira P, Vitorino R, Colaço B, Pires MJ, Márquez M, Castellanos E, Neuparth MJ, 
Teixeira C, Costa C, Moreira-Gonçalves D, Cabral S, Duarte JA, Santos LL, Amado F, Ferreira R. 
Int J Biochem Cell Biol. 2013. Jul; 45(7):1399-409. doi: 10.1016/j.biocel.2013.04.014. 
 
 65 
 
 66 
 
 67 
 
 68 
 
 69 
 
 70 
 
 71 
 
 72 
 
 73 
 
 74 
 
 75 
 
  
 76 
 
3.1.2 Paper III 
Overexpression of tumour-associated carbohydrate antigen Sialyl-Tn in advanced 
bladder tumours. 
Ferreira JA, Videira Pa, Lima L, Pereira S, Silva M, Carrascal M, Severino PF, Fernandes E, 
Almeida A, Costa C, Vitorino R, Amaro T, Oliveira MJ, Reis CA, Dall’Olio F, Amado F, Santos LL. 
Mol Oncol. 2013. Jun;7(3):719-31. doi: 10.1016/j.molonc.2013.03.001. 
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3.2 Effect of mTor inhibitors on bladder cancer cells 
Recently it has been reported that mTOR inhibitors could have an important role to play in 
bladder-cancer treatment and may restore chemosensitivity in resistant tumours  
3.2.1 Paper IV 
Everolimus combined with cisplatin has a potential role in treatment of urothelial 
bladder cancer. 
Pinto-Leite R, Arantes-Rodrigues R, Palmeira C, Colaço B, Lopes C, Colaço A, Costa C, da Silva 
VM, Oliveira P, Santos L. 
Biomed Pharmacother. 2013. Mar; 67(2):116-21. doi: 10.1016/j.biopha.2012.11.007. 
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3.3 Patient-derived bladder cancer xenografts  
Patient-derived tumour xenografts (PDTXs) have been shown to be a highly predictive model to 
test standard chemotherapy and for identification of tumour types that might benefit from new 
treatments in clinical trials.  
3.3.1 Paper V 
Patient-derived bladder cancer xenografts: a systematic review. 
Bernardo C, Costa C, Sousa N, Amado F, Santos L 
Transl Res. 2015. Feb 12. pii: S1931-5244(15)00040-7. doi: 0.1016/j.trsl.2015.02.001. 
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3.3.2 Paper VI  
Patient-derived sialyl-Tn-positive invasive bladder cancer xenografts in nude mice: 
an exploratory model study. 
Bernardo C, Costa C, Amaro T, Gonçalves M, Lopes P, Freitas R, Gärtner F, Amado F, Ferreira JA, 
Santos L. 
Anticancer Res. 2014. Feb; 34(2):735-44. 
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4 Synoptic list of the relevant results 
 
 121 
 
We aim in this chapter to present in a synthetic way the most relevant results observed in the 
several scientific articles that integrate the PhD thesis. 
 
A. Evaluation of the expression and PI3K/Akt/mTOR pathway activation and STn in bladder 
cancer.  
 
 STn antigen expression was associated with muscle invasion when compared to NMIBC 
(p=0,001) and correlates with decreased CSS (CSS – cancer specific survival is defined as 
the period between the tumour removal by surgery and either patient death by cancer 
or the last follow-up information; log rank p=0,024); 
 STn was an independent prognostic marker of worst CSS; 
 Tn antigen expression in NMBC and MIBC was residual;  
 PI3K/Akt/mTOR pathway related molecules showed an equal and heterogeneous 
distribution between NMIBC and MIBC and could not be associated with stage of 
disease and CSS; 
 PTEN negative phenotype was significantly associated with muscle invasion;  
 PTEN negative tumours had lower CSS (p=0,015);  
 Overexpression of pAKT, pmTOR and/or pS6 allowed discriminating STn-positive 
advanced stage bladder tumours facing worst CSS (p=0,027); 
 Overexpression of PI3K/AKT/mTOR pathway proteins in STn+ MIBC was independently 
associated with risk of death by cancer: 6-fold higher, p=0,039); 
 STn is a marker of poor prognosis in bladder cancer. Its combination with 
PI3K/AKT/mTOR pathway evaluation has potential to be used in disease stage 
stratification; 
 Several MIBC presented an increased pS6 staining intensity in the invasion front.  
To use murine chemically induced urothelial tumours treated with Sirolimus to assess the 
impact of mTOR inhibitors on cell protein expression 
 Mice treated with sirolimus presented decreased number of invasive lesions and 
concomitantly decreased expression of pS6 and STn; 
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 Mice experiments suggested that mTOR pathway inhibition with sirolimus has 
therapeutic potential in MIBC. 
To evaluate the regulation of PI3K/Akt/mTOR and activation of the ubiquin- proteosome 
pathways in bladder cancer- induced skeletal muscle wasting 
 The histologic evidences of non-muscle-invasive bladder tumours observed in BBN 
animals were related to 17% loss of body weight- caquexia; 
 High serum levels of pro-inflammatory mediators and myostatin and high levels of 
urinary MMPs; 
 Decreased oxidative metabolism in wasted muscle; 
 Reduced levels of pAKT, mTOR and P70S6K were observed; 
 It was observed activation of the ubiquitin-proteasome protein degradation pathway 
and suppression of PI3K/AKT/mTOR pathway. 
Expression of STn in bladder tumours its correlation with tumour proliferation and clinical 
outcome 
 75% of the high-grade bladder tumours, presenting elevated proliferation rates and high 
risk of recurrence/progression expressed STn,  mainly in non-proliferative areas of the 
tumour - in cells invading the basal and muscle layers; 
 STn was found in tumour-adjacent mucosa but  was not expressed by the normal 
urothelium; 
 STn expression correlates with the concomitant increase of cell motility and invasive 
capability. 
B. Everolimus (RAD001) combination with Cisplatin as a potential strategy to achieve high 
levels of efficacy with lower cytotoxicity 
 
 Treatment with cisplatin  statistically significantly (P<0.05) decreased cell proliferation in 
cell lines in a dose-dependent manner : cell- cycle arrest in the late S/G2 phase followed 
by a higher apoptotic rate; 
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 Combination of everolimus and cisplatin or gemcitabine decreased the proliferation of 
bladder cancer cell lines -statistically significant (P<0.05) in comparison to the 
chemotherapy agent alone; 
 The NMI cancer cell line was the most sensitive to the action of the combination 
everolimus/cisplatin. 
C. Direct bladder cancer xenografts model 
 
 It was stablished tumour xenografts with preservation of the original tumour identity 
but variable take rate; 
 Advanced stage and high grade tumours were associated with increased take rate; 
 Histology and immunoexpression of tumour markers (p53, p63, Ki-67, CK20, STn) were 
similar between primary tumours and xenografts; 
 p53 and ki-67 levels of expression increased; 
 STn expression, even though decreased, was preserved in xenografts - STn-positive 
xenograft model. 
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5 Final Discussion and Conclusions 
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Bladder cancer is the second most common cancer of the urinary tract [Willems and Stein, 
2004] and in Portugal according to Roreno was one of the malignant diseases more frequent in 
man resulting in 721 deaths [Roreno, 2008 and Ferlay et al, 2010]. 
Bladder cancer is a heterogeneous disease whether in pathology or in the response to 
therapeutics urging to develop new strategies of research and selecting the best treatments 
[Kaufman et al, 2009]. 
NMIBC represents about 75% of the newly diagnosed cases and are characterized by a high 
recurrence rate [Holmang et al, 1995]. MIBC represents 20-30% of the cases and treatment 
includes cystectomy and cisplatin-based chemotherapy regime. Fifty percent of this patient will 
relapse and progress to metastatic disease. For both groups we need to develop new drugs 
with higher efficacy and lower cytotoxicity [Bernardo et al, 2014]. 
The PI3K/AKT/mTOR is an important signaling cascade determinant for cell growth and 
proliferation and disruption along this pathway can result in altered cell dynamics and tumour 
development.   
mTOR pathway alterations have been shown to occur in bladder cancer, such as PIK3CA gene 
mutations, elevations of pAKT levels and loss of TSC1 function [Ching and Hansel, 2010]. The 
aberrant activation of this pathway has been suggested to contribute to invasion [Wu et al, 
2004]. Previous studies also demonstrated that STn overexpression is a key player in a subset of 
advanced stage tumours making the STn antigen a potential anti-cancer target [Ferreira et al, 
2013]. 
In the group of scientific articles presented in this thesis we intended to evaluate the expression 
of PI3K/AKT/mTOR activation in bladder cancer both in humans and in a chemical induced 
murine model. We found that PI3K/AKT/mTOR pathway related molecules show an equal 
distribution between NMIBC and MIBC and did not associated with stage of disease. Thus 
activation of mTOR pathway proteins did not discriminate the stage of disease or a worse 
prognosis reinforcing previous observations [Korkolopoulou et al, 2012; Fahmy et al 2013]. In 
contrast we found that PTEN expression was decrease in advanced stage tumours as previously 
reported [Saal et al, 2007]. We also observed that PTEN negative MIBC was significantly 
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associated with muscle invasion and lower CSS. According with previous observations PTEN 
expression exerts a suppressive effect over the PI3K/AKT/mTOR pathway which may account 
for poorer outcome [Sun et al, 2011; Calderaro et al, 2014].    
STn expression is associated with muscle invasive and correlate with decrease survival as 
previously observed in different cancer models such as gastric tumours [Tsuchiya et al, 1995]. In 
bladder cancer is expressed mainly in advanced stages cases [Ferreira et al, 2013]. It seems that 
STn expression altered cancer cells properties being a key event leading to metastasis also 
observed by Lin and colleagues [Lin et al, 2009]. Overexpression of PI3K/AKT/mTOR pathway 
biomarkers were associated with worse CSS in STn positive advanced stage tumours.  
These results suggest that these aggressive tumours may be good candidate to mTOR inhibitors 
therapeutics combining drugs targeting STn expressing cells, although these preliminary results 
were obtained from a relatively low number of patients.  
Regarding PTEN, we observed that PTEN negative MIBC presented worse CSS in comparison to 
PTEN positive lesions. PTEN expression was decreased in advanced stage tumours as previously 
reported [Sun et al, 2011; Calderaro et al, 2014]. 
Using murine chemically induced urothelial tumours we assessed the impact of mTOR inhibitors 
on cell protein expression, with sirolimus. Mice treated with sirolimus presented a decrease 
number of invasive tumours and concomitantly decreased expression of pS6 and STn, as 
supported by Oliveira and colleagues 2009 [Oliveira et al, 2009].  Using this model we reinforce 
that sirolimus reduce the frequency of tumours with invasive potential and significantly 
decreased the expression of pS6, one of the downstream effectors of the PI3K/AKT/mTOR. The 
administration of sirolimus was effective against STn positive cells – we describe for the first 
time that chemically-induced bladder tumours express this antigen in contrast with most of the 
available bladder cancer cell lines. These observations also demonstrate for the first time an 
association between PI3K/AKT/mTOR and STn in invasive tumours (STn antigen is biomarker of 
poor prognosis). This also provides the first link between two related events in bladder cancer - 
PI3K/AKT/mTOR activation and altered glycosylation. More studies need to be done before 
progressing to clinical trials. 
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The role of the mTOR inhibitors was also evaluated using bladder cancer cell lines. Regarding 
this topic and the combination of everolimus with cisplatin as potential strategy to use in 
bladder cancer achieving high levels of efficacy with lower cytotoxicity we published the 
following results: treatment with cisplatin statistically decreased cell proliferation in cell lines in 
dose dependent manner (p<0.05). Cell cycle arrested in the late S/G2 phase followed by a high 
apoptotic rate. Combination therapy was already performed previously in some preclinical 
studies namely on advanced solid tumours [Fury et al, 2012]. Combination of everolimus and 
cisplatin decreased the proliferation of bladder cancer cell lines in comparison to the 
chemotherapy agent alone (p<0,05). The anti-proliferative activity of cisplatin combined with 
everolimus could be a useful anticancer treatment for patients with bladder cancer. We also 
observed that the NMIBC cell line was the most sensitive to the action of combined 
cisplatin/everolimus, thus opening a new line of research in this group of bladder tumours. 
To evaluate the correlation between the expression of PI3K/AKT/mTOR pathway activation in 
bladder cancer-induced skeletal muscle wasting we found that in rat model BBN induced 
urothelial carcinoma there was a 17% of body weight loss - cachexia. These tumours were 
equivalent to the NMIBC observed in humans, a well-stablished model of tumours of the 
urinary tract [Palmeira et al, 2009]. It was also observed high serum levels of pro-inflammatory 
mediators, myostatin, high levels of urinary MMPs and decreased oxidative metabolism in 
wasted muscle supporting a catabolic profile associated with carcinoma-induced muscle 
wasting. We found reduce levels of pAKT, mTOR and P70S6K suggesting unbalance between 
protein synthesis and degradation as previously suggested [Fanzani et al, 2012]. We observed 
activation of the ubiquitin-proteossome protein degradation pathway and suppression of 
PI3K/AKT/mTOR pathway. A therapeutic measure that prevents/counteract this imbalance 
might limit comorbid disease and consequently enhance patients’ quality of life. 
Regarding the expression of STn in bladder carcinomas and its correlation with tumour 
proliferation and clinical relevance we found that 75% of the high grade bladder tumours, 
expressing STn presented elevated proliferation rates and high risk of recurrence/progression, 
as previously observed by Davidson and colleagues [Davidson et al, 2000]. This 75% was found 
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mainly in non-proliferative areas of the tumour, in cells invading the basal and muscle layers. 
Thus STn was correlated with the depth of invasion and metastization [Ikeda et al, 1993].  
STn expression seems to correlate with the concomitant increase of cell motility and invasive 
capability but despite this observation there is still little information regarding STn expression in 
bladder cancer. Furthermore it was not express by the normal urothelium demonstrating the 
cancer-specific nature of this antigen. 
As referred before more studies need to be done before progressing to clinical trials. Human 
tumour xenograft models have been developed for several types of cancer however in the case 
of human bladder cancer few studies are available [Bernardo et al, 2015].  
We established a xenograft model of bladder cancer suitable for comparison between tumour 
response in mice and clinical outcome in human bladder tumours. In the group of scientific 
articles that resulted from this work we studied the best methodology to develop a tumour 
xenograft model of bladder cancer preserving the original tumour identity. Although previous 
studies suggested a correlation between engraftment success and clinical prognosis there is still 
few evidence of this association [Bellmunt et al, 2009].  We observed advanced stage and high 
grade tumours were associated with increase take rate. Mores studies need to be done before 
stablish the model suitable for drugs testing. 
Histology and imunoexpression of tumour markers (p53, p63, KI-67, CK20, STn) were similar 
between primary tumours and xenograft.  However p53 and Ki-67 levels of expression 
increased suggesting a tendency for the most aggressive and rapidly growing cells from a 
heterogeneous primary tumour during the engraftment process as observed before [Talmadge, 
2007]. STn expression even though decreased was preserved in xenografts reinforcing a STn 
positive xenograft model. Given the pancarcinoma nature of STn antigen expression, its 
association with invasion and metastases, these findings may constitute valuable insights for 
other tumours.  
The published results included in the present thesis show that the activation of PI3K/AKT/mTOR 
pathway is present either in NMIBC and MIBC, suggesting a key role in bladder cancer 
carcinogenesis. Moreover chemosensibility was observed in both bladder cancer groups when 
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mTOR inhibitors were used. These results suggested that the combination of these molecules 
with the established therapeutic drugs may be potential strategy to use in bladder cancer 
achieving high levels of efficacy with lower cytotoxicity. To achieve this goal the new 
experimental bladder cancer models, namely xenografts models, are very important, allowing 
the study of these new molecular targets and evaluate the tumour response to these new drugs 
or drug combinations in the field of urologic oncology. 
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The series of studies presented in this PhD thesis have the purpose to identify more effective 
therapeutic targets for bladder cancer due to its recurrence and potential to progress to 
invasion, especially the ones with poor prognosis. Alterations in the activation of the 
PI3K/Akt/mTOR pathway are key events in bladder cancer development. New studies that allow 
a better understanding of the upstream and downstream mTOR pathway regulation should be 
performed.  
We also addressed the expression of STn, a cancer associated antigen and its possible 
association with active PI3K/Akt/mTOR in invasive tumors. Tumours presenting positive pmTOR 
and/or pS6 showed a trend towards decrease survival in MIBC STn positive. Such results 
suggest that these tumours may be good candidate to mTOR inhibitors therapeutics such as 
sirolimus combined therapeutics against STn-expressing cells. These results should be 
confirmed with a large series of bladder cancer patients and other mTOR inhibitors may be 
assayed. 
As a complement to this work we studied patient- derived tumor xenografts and its possible 
use to compare tumor response and resistance to drugs, in bladder cancer. We established a 
xenograft model that preserved the original tumour identity and could be used for comparison 
between tumour response in mice and clinical outcome in human bladder tumours. We also 
access the potential of combined Everolimus with Cisplatin in bladder cancer cell lines as a 
useful anti-cancer drug therapy.  
In the future, using standard animal models, xenografts or cell lines we may access the 
importance of the inhibitors of the PI3K/Akt/mTOR pathway and use it for drug testing and 
identification of prognostic biomarkers; also further studies regarding PI3K/Akt/mTOR pathway 
abnormalities need to be addressed for patient stratification and personalized therapies not 
only for bladder but also for other types of cancer. 
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